Cardiology
Latest News
Risk factors for death from COVID-19 identified in Wuhan patients
The odds of dying in the hospital increased with age, higher SOFA score, and D-dimer level exceeding 1 mcg/L.
Conference Coverage
Exercise needn’t be strenuous to reduce heart risk
PHOENIX – “Find the things you love to do and get moving,” Dr. Andrea Z. LaCroix advises.
From the Journals
What are the most prescribed medications for type 2 diabetes?
Empagliflozin and dulaglutide were the most-prescribed drugs in their respective classes for treating type 2 diabetes over 5 years.
Conference Coverage
Beginning estrogen soon after menopause slows atherosclerosis progression
PHOENIX – The study raises a critical question: Is there a time period where getting hormone therapy would be most beneficial for the heart?
From the Journals
MACE benefits with dapagliflozin improve with disease duration
Findings suggest treatment with the SGLT-2 inhibitor should be initiated early in some high-risk patients.
From the Journals
Prescription cascade more likely after CCBs than other hypertension meds
From the Journals
Varied nightly bedtime, sleep duration linked to CVD risk
Circadian disruption may occur outside of shift work and accumulate over time, particularly given modern lifestyle factors such as increased use...
Latest News
Bad behavior by medical trainees target of new proposal
Unprofessional behaviors by medical trainees are universally deemed egregious and worthy of discipline, but often these lapses may offer teachable...
Applied Evidence
Avoiding missteps in BP measurement
Making sure a patient is seated properly is just one way to ensure an accurate measurement. But steering clear of certain methods of measurement...
Conference Coverage
More evidence backs LDL below 70 to reduce recurrent stroke
LOS ANGELES – Targeting LDL below 70 mg/dL for more than 5 years avoided more than one in four subsequent major cardiovascular events among adults...
News
Dulaglutide OK for primary, secondary CV risk reduction in U.S.
This marks the first time a GLP-1 receptor agonist for type 2 diabetes has been approved for primary prevention of CV events.